H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $39

Moomoo NewsMar 21 13:31 ET · Ratings

Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 21 08:02 ET · Ratings

Enliven Therapeutics Analyst Ratings

BenzingaMar 21 07:50 ET · Ratings

Express News | Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $39 From $37

ReutersMar 21 06:09 ET

Insider Sale: PRESIDENT AND CEO of $ELVN Sells 12,500 Shares

Quiver QuantitativeMar 19 17:46 ET

LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsMar 14 12:31 ET · Ratings

Enliven Therapeutics: Promising Clinical Progress and Strong Financial Position Justify Buy Rating

TipRanksMar 14 08:05 ET · Ratings

TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating

Moomoo NewsMar 13 19:31 ET · Ratings

ENLIVEN THERAPEUTICS Earnings Results: $ELVN Reports Quarterly Earnings

Quiver QuantitativeMar 13 16:30 ET

Enliven Therapeutics | 10-K: FY2024 Annual Report

SECMar 13 16:16 ET · Announcements

Earnings Flash (ELVN) Enliven Therapeutics Posts Q4 Loss $-0.46 Per Share

MT NewswiresMar 13 16:10 ET

Enliven Therapeutics | 8-K: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

SECMar 13 16:10 ET · Announcements

Express News | Enliven Therapeutics Q4 Basic EPS USD -0.46

ReutersMar 13 16:05 ET

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

PR NewswireFeb 25 16:05 ET

Enliven Therapeutics: Promising Innovations in Tyrosine Kinase Inhibitors and Strategic Growth Plans Justify Buy Rating

TipRanksFeb 5 13:45 ET · Ratings

Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39

Moomoo NewsFeb 4 01:32 ET · Ratings

Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001's High Selectivity and Promising Clinical Data

TipRanksFeb 4 00:35 ET

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans

Yahoo FinanceJan 31 10:10 ET

Enliven Therapeutics Insider Sold Shares Worth $685,868, According to a Recent SEC Filing

MT NewswiresJan 10 17:37 ET

Insider Sale: CHIEF FINANCIAL OFFICER of $ELVN (ELVN) Sells 900 Shares

Quiver QuantitativeDec 31 17:31 ET